New immunotherapy combo shows promise for advanced liver cancer
NCT ID NCT05883644
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as the first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tumors. The goal is to control the disease and improve survival, but it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Shreveport, Louisiana, 71103, United States
-
Research Site
Detroit, Michigan, 48202, United States
-
Research Site
Bobigny, 93000, France
-
Research Site
Clichy, 92110, France
-
Research Site
Créteil, 94010, France
-
Research Site
Marseille, 13005, France
-
Research Site
Rennes, 35000, France
-
Research Site
Berlin, D-13353, Germany
-
Research Site
Cologne, 50937, Germany
-
Research Site
Frankfurt, 60488, Germany
-
Research Site
Lübeck, 23538, Germany
-
Research Site
Hong Kong, 0000, Hong Kong
-
Research Site
Shatin, 00000, Hong Kong
-
Research Site
Milan, 20132, Italy
-
Research Site
Naples, 80147, Italy
-
Research Site
Padova, 35128, Italy
-
Research Site
Pisa, 56126, Italy
-
Research Site
Rozzano, 20089, Italy
-
Research Site
Turin, 10128, Italy
-
Research Site
Kanazawa, 920-8641, Japan
-
Research Site
Kashiwa, 277-8577, Japan
-
Research Site
Matsuyama, 790-0024, Japan
-
Research Site
Musashino-shi, 180-8610, Japan
-
Research Site
Osakasayama-shi, 589-8511, Japan
-
Research Site
Yokohama, 241-8515, Japan
-
Research Site
Singapore, 119228, Singapore
-
Research Site
Singapore, 169610, Singapore
-
Research Site
Singapore, 308433, Singapore
-
Research Site
Gyeonggi-do, 13620, South Korea
-
Research Site
Seongnam-si, 13496, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 8035, Spain
-
Research Site
Córdoba, 14004, Spain
-
Research Site
Madrid, 28007, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Hanoi, 100000, Vietnam
Conditions
Explore the condition pages connected to this study.